FDA Pre-Announced BIMO Inspections Could Reduce Process Delays
This article was originally published in The Gray Sheet
Executive Summary
The bioresearch monitoring (BIMO) reengineering team within FDA's Center for Devices and Radiological Health is considering the use of pre-announced inspections of sponsors of medical device clinical investigations.